Omeros Q2 2026: YARTEMLEA Sales Surge, Debt Repurchases Cut Dilution
OMER has more than doubled off its 52-week low of $3.94.
Summary
Omeros delivered strong Q2 results with YARTEMLEA sales surging and net income positive. Debt repurchases and share buybacks reduced dilution, while cash runway extends beyond 12 months.
Key Events · Earnings and Guidance · OMER
-
YARTEMLEA Sales Surge
Net product sales of $28.5 million in Q2 2026, up 190% quarter-over-quarter, with 73 unique accounts ordering by June 30.
-
Net Income Positive
Net income of $13.2 million for Q2 2026, compared to a net loss of $25.4 million in Q2 2025, driven by product sales and a non-cash gain on derivative remeasurement.
-
Debt Repurchases Reduce Dilution
Repurchased $30.5 million principal of 2029 Notes for $60.2 million, reducing potential dilution by 5.8 million shares and eliminating $8.6 million in future interest payments.
-
Share Buybacks Continue
Repurchased 0.8 million shares for $9.9 million during H1 2026 under the $100 million program, with $90.1 million remaining authorized.
Analysis · OMER · Life Sciences
Omeros reported its first full quarter of YARTEMLEA sales with net revenue of $28.5 million, up 190% quarter-over-quarter, driving net income of $13.2 million. The company also repurchased $30.5 million of convertible notes, reducing potential dilution by 5.8 million shares, and bought back 0.8 million shares for $9.9 million. Cash stands at $132 million, funding operations for over 12 months. The EMA negative opinion on narsoplimab remains a key risk, but the U.S. launch momentum and balance sheet actions are positive.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OMER was trading at $16.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $992.3M. The 52-week trading range was $3.94 to $17.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.